News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
469,688 Results
Type
Article (18006)
Company Profile (81)
Press Release (451601)
Section
Business (141341)
Career Advice (723)
Deals (26297)
Drug Delivery (81)
Drug Development (56471)
Employer Resources (78)
FDA (13441)
Job Trends (9987)
News (243449)
Policy (23443)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Elite (1)
Academia (917)
Accelerated approval (1)
Adcomms (12)
Allergies (63)
Alliances (36900)
ALS (44)
Alzheimer's disease (744)
Antibody-drug conjugate (ADC) (58)
Approvals (13487)
Artificial intelligence (133)
Autoimmune disease (11)
Automation (11)
Bankruptcy (212)
Best Places to Work (8113)
BIOSECURE Act (12)
Biosimilars (93)
Biotechnology (52)
Bladder cancer (34)
Brain cancer (12)
Breast cancer (120)
Cancer (1210)
Cardiovascular disease (95)
Career advice (617)
Career pathing (8)
CAR-T (111)
Cell therapy (327)
Cervical cancer (15)
Clinical research (47048)
Collaboration (544)
Compensation (200)
Complete response letters (14)
COVID-19 (1472)
CRISPR (24)
C-suite (136)
Cystic fibrosis (57)
Data (1422)
Denatured (14)
Depression (22)
Diabetes (198)
Diagnostics (4312)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (8)
Drug discovery (67)
Drug pricing (62)
Drug shortages (26)
Duchenne muscular dystrophy (59)
Earnings (60437)
Editorial (17)
Employer branding (8)
Employer resources (63)
Events (66930)
Executive appointments (457)
FDA (14343)
Featured Employer (22)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (393)
Gene editing (64)
Generative AI (11)
Gene therapy (211)
GLP-1 (461)
Government (2781)
Grass and pollen (3)
Guidances (39)
Healthcare (10818)
Huntington's disease (11)
IgA nephropathy (18)
Immunology and inflammation (56)
Indications (23)
Infectious disease (1559)
Inflammatory bowel disease (72)
Inflation Reduction Act (6)
Influenza (38)
Intellectual property (66)
Interviews (98)
IPO (11886)
IRA (28)
Job creations (2224)
Job search strategy (548)
Kidney cancer (7)
Labor market (13)
Layoffs (265)
Leadership (6)
Legal (4705)
Liver cancer (45)
Lung cancer (181)
Lymphoma (91)
Machine learning (2)
Management (39)
Manufacturing (264)
MASH (35)
Medical device (10791)
Medtech (10795)
Mergers & acquisitions (14802)
Metabolic disorders (439)
Multiple sclerosis (50)
NASH (8)
Neurodegenerative disease (38)
Neuropsychiatric disorders (7)
Neuroscience (1023)
NextGen: Class of 2025 (3615)
Non-profit (1224)
Northern California (1645)
Now hiring (10)
Obesity (223)
Opinion (130)
Ovarian cancer (39)
Pain (53)
Pancreatic cancer (48)
Parkinson's disease (78)
Partnered (10)
Patents (161)
Patient recruitment (61)
Peanut (36)
People (37709)
Pharmaceutical (34)
Pharmacy benefit managers (6)
Phase I (14194)
Phase II (20569)
Phase III (16235)
Pipeline (854)
Podcasts (23)
Policy (60)
Postmarket research (1569)
Preclinical (5410)
Press Release (67)
Prostate cancer (64)
Psychedelics (14)
Radiopharmaceuticals (176)
Rare diseases (214)
Real estate (3957)
Recruiting (29)
Regulatory (17432)
Reports (24)
Research institute (901)
Resumes & cover letters (86)
Rett syndrome (2)
RNA editing (2)
RSV (25)
Schizophrenia (37)
Series A (62)
Series B (42)
Service/supplier (7)
Sickle cell disease (32)
Southern California (1444)
Special edition (9)
Spinal muscular atrophy (112)
Sponsored (17)
Startups (2290)
State (1)
Stomach cancer (2)
Supply chain (57)
The Weekly (8)
United States (14553)
Vaccines (389)
Venture capitalists (14)
Webinars (4)
Weight loss (153)
Women's health (22)
Worklife (8)
Date
Today (163)
Last 7 days (533)
Last 30 days (1988)
Last 365 days (23664)
2025 (5573)
2024 (24942)
2023 (29094)
2022 (38889)
2021 (41700)
2020 (39678)
2019 (31150)
2018 (23758)
2017 (24606)
2016 (22487)
2015 (26875)
2014 (19414)
2013 (15974)
2012 (17776)
2011 (18440)
2010 (16238)
Location
Africa (398)
Alabama (29)
Alaska (2)
Arizona (100)
Arkansas (9)
Asia (30404)
Australia (4877)
California (3724)
Canada (1308)
China (370)
Colorado (153)
Connecticut (170)
Delaware (81)
Europe (64161)
Florida (574)
Georgia (155)
Hawaii (1)
Idaho (38)
Illinois (341)
India (19)
Indiana (233)
Iowa (4)
Japan (114)
Kansas (79)
Kentucky (6)
Louisiana (3)
Maine (62)
Maryland (617)
Massachusetts (2633)
Michigan (203)
Minnesota (228)
Mississippi (1)
Missouri (64)
Montana (20)
Nebraska (13)
Nevada (42)
New Hampshire (48)
New Jersey (1288)
New Mexico (23)
New York (1112)
North Carolina (627)
North Dakota (6)
Northern California (1645)
Ohio (131)
Oklahoma (8)
Oregon (24)
Pennsylvania (909)
Puerto Rico (8)
Rhode Island (17)
South America (741)
South Carolina (14)
South Dakota (1)
Southern California (1444)
Tennessee (63)
Texas (511)
Utah (89)
Virginia (102)
Washington D.C. (30)
Washington State (346)
West Virginia (3)
Wisconsin (31)
469,688 Results for "implandata ophthalmic products gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO
Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.
June 13, 2024
·
3 min read
Press Releases
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH
March 19, 2025
·
1 min read
Press Releases
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
February 14, 2025
·
5 min read
Pharm Country
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.
April 25, 2024
·
10 min read
Press Releases
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers
February 25, 2025
·
3 min read
Press Releases
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
March 21, 2025
·
2 min read
Business
Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH
Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.
April 9, 2024
·
2 min read
Press Releases
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
January 14, 2025
·
3 min read
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05%, a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
March 13, 2024
·
9 min read
Press Releases
Niterra Ventures Company Invests $18M Additional Funding in Neoplas Med GmbH
November 25, 2024
·
4 min read
1 of 46,969
Next
